FDMT (4D Molecular Therapeutics) Moat Score: 5/10 (As of Jun. 27, 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.60
GF Value $214.49
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Moat Score?

4D Molecular Therapeutics FDMT +0.69% 55 Moat Score is 5 as of Jun. 27, 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.49 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,404 Biotechnology companies, 4D Molecular Therapeutics ranks better than 96.72% on this metric.

4D Molecular Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

4D Molecular Therapeutics has Narrow Moat: 4D Molecular Therapeutics Inc has a solid narrow moat due to its valuable intellectual property and patents in gene therapy. The company benefits from significant R&D capabilities and some regulatory barriers, but lacks strong brand strength and customer loyalty to elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes 4D Molecular Therapeutics might have Narrow Moat - Solid narrow moat.

4D Molecular Therapeutics  (NAS:FDMT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

4D Molecular Therapeutics Moat Score Related Terms

FDMT vs KYTX, XOMA, OVID: Moat Score Comparison

For the Biotechnology subindustry, 4D Molecular Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4D Molecular Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Moat Score falls into.


FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
4D Molecular Therapeutics (FDMT) has a Moat Score of 5 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, 4D Molecular Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, placing it in the top 3.3%.
Is 4D Molecular Therapeutics' Moat Score too high?
4D Molecular Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. 4D Molecular Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Moat Score compare to KYTX and XOMA?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #46 out of 1404 companies for Moat Score. This places 4D Molecular Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. 4D Molecular Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.49, compared to a current price of $11.60 — trading 94.6% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Moat Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.60 is trading 94.6% below its estimated GF Value™ of $214.49. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Moat Score: 5
  • GF Value™: $214.49 vs. price of $11.60 (94.6% below fair value)
  • GF Score™: 55/100 with 7 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1404)

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.60
Price
$214.49
GF Value